Femme et Homme
- | Pays :
- Belgium
- | Organes : -
- | Spécialités : -
Extrait
This study is a 5 day, single-center, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of Somatostatin used as inflow modulator in liver transplantation. Patient systemic and hepatic dynamics will be collected and recorded at predefined time-points. To evaluate the ischemia-reperfusion injury, it is planned to perform liver biopsies at two different time-points to compare the liver structure and proteomic variations.
Critère d'inclusion
- Liver Transplant With Clinically Significant Portal Hypertension